Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleAdjuvant Radiotherapy of Sintilimab Versus TACE for HCC
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 286
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07186621 - Phase 1/2Not yet taking people in ChinaEDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 62
- Run by
- Zhongda Hospital
See details and how to joinNCT07187284 - Phase 1Enrolling by invitationJS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
- Where
- Changsha
- Age
- 18 years to 75 years
- People
- 20
- Run by
- Xiangya Hospital of Central South University
See details and how to joinNCT06882876 - No phaseNot yet taking people in ChinaThe Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study
- Where
- Guiyang, Haikou, Jiaozuo, Kaifeng, Luohe, Luoyang, Nanchang, Nanyang, Shangqiu, Zhoukou
- Age
- 18 years to 80 years
- People
- 118
- Run by
- Xuhua Duan
See details and how to joinNCT07180459 - No phaseTaking peopleA Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 1,800
- Run by
- Yingbin Liu, MD, PhD, FACS
See details and how to joinNCT07176962 - Early phase 1Taking peopleSafety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
- Where
- Hefei
- Age
- 19 years to 70 years
- People
- 36
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07106814 - No phaseTaking peopleObservation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.
- Where
- Anyang, Guangzhou, Hebi, Jiaozuo, Jiayuguan, Jinan, Jiyuan, Kaifeng, Linyi, Luohe, Luoyang, Nanyang, Ningbo, Pingdingshan, Pingdu, Pujiang, Rizhao, Sanmenxia, Shangqiu, Xinxiang, Xinyang, Xuchang, Yantai, Zhengzhou, Zhongshan, Zhoukou, Zhumadian, Zibo
- Age
- 18 years and over
- People
- 15,000
- Run by
- The First Affiliated Hospital of Zhengzhou University
See details and how to joinNCT07169656 - No phaseNot yet taking people in ChinaYueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 210
- Run by
- Fudan University
See details and how to joinNCT07169916 - No phaseTaking peopleComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Where
- Beijing, Chengdu, Dazhou, Fuzhou, Guangzhou, Guiyang, Kunming, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- Age
- 18 years to 18 years
- People
- 400
- Run by
- Chinese Academy of Sciences
See details and how to joinNCT07170345 - No phaseNot yet taking people in ChinaA Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 55
- Run by
- Mao-Lin Yan
See details and how to joinNCT07164703 - Phase 2Not yet taking people in ChinaDisitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 65
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07159217 - No phaseTaking peopleRisk Assessment for HBV-Related Liver Cancer
- Where
- Guangzhou
- Age
- 30 years to 75 years
- People
- 6,000
- Run by
- Sun Yat-sen University
See details and how to joinNCT07160946 - No phaseNot yet taking people in ChinaA Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
- Where
- Dengzhou, Haikou, Jiaozuo, Kaifeng, Luoyang, Nanchang, Shangqiu, Wuxi, Xingtai, Zhengzhou, Zhoukou
- Age
- 18 years and over
- People
- 2,000
- Run by
- Xuhua Duan
See details and how to joinNCT07156617 - Phase 2Not yet taking people in ChinaGecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
- Where
- Tianjin
- Age
- 18 years to 80 years
- People
- 35
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07157306 - Phase 2Taking peopleApatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years to 70 years
- People
- 27
- Run by
- Wei Zhang
See details and how to joinNCT07154082 - No phaseTaking peopleMiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 204
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07156058 - Phase 1Taking peopleSON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- Where
- Beijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi’an
- Age
- 18 years to 75 years
- People
- 96
- Run by
- Qurgen Inc.
See details and how to joinNCT06873659 - Phase 1/2Taking peopleA Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT06902389 - No phaseTaking peopleAI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 353
- Run by
- Tongji Hospital
See details and how to joinNCT07062380 - Phase 2Not yet taking people in ChinaIparomlimab and Tuvonralimab Combined With GC in Advanced ICC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 104
- Run by
- Fudan University
See details and how to joinNCT07152769 - Phase 2Taking peopleLparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
- Where
- Tianjin
- Age
- 18 years and over
- People
- 29
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07099274 - No phaseTaking peopleThe Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
- Where
- Hengyang
- Age
- 18 years to 75 years
- People
- 800
- Run by
- The First Affiliated Hospital of University of South China
See details and how to joinNCT07147335 - Phase 2Not yet taking people in ChinaCryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.
- Where
- Shanghai
- Age
- 18 years and over
- People
- 36
- Run by
- Fudan University
See details and how to joinNCT07147088 - No phaseTaking peopleA Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 286
- Run by
- Li Qiang
See details and how to joinNCT07070076 - No phaseTaking peopleThe Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
- Where
- Guilin, Shaoyang, Zhanjiang
- Age
- 18 years and over
- People
- 700
- Run by
- Guilin Medical University, China
See details and how to joinNCT07141056